FENC - NASDAQ

Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc.

FENC·NASDAQ

$9.98

-8.4%
HealthcareBiotechnology

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$285.23M
EPS-0.3600
P/E Ratio-22.59
Earnings Date08/13/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. Earnings Call Transcripts

FENC · NASDAQ

Related Guides

Blog Categories

Continue your FENC research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.